Core Viewpoint - ModivCare reported a significant quarterly loss of $1.71 per share, which was much worse than the Zacks Consensus Estimate of a loss of $0.34, indicating a substantial earnings surprise of -402.94% [1] Financial Performance - The company posted revenues of $650.65 million for the quarter ended March 2025, slightly exceeding the Zacks Consensus Estimate by 0.96%, but down from $684.45 million in the same quarter last year [2] - Over the last four quarters, ModivCare has surpassed consensus EPS estimates only once, while it has topped consensus revenue estimates two times [2] Stock Performance - ModivCare shares have declined approximately 88.6% since the beginning of the year, contrasting sharply with the S&P 500's decline of only -4.3% [3] Future Outlook - The company's earnings outlook is critical for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.06 on revenues of $653.77 million, and for the current fiscal year, it is -$0.16 on revenues of $2.64 billion [7] Industry Context - The Medical Services industry, to which ModivCare belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Another company in the same industry, HealthEquity, is expected to report quarterly earnings of $0.81 per share, reflecting a year-over-year increase of 1.3% [9]

Core Viewpoint - LifeMD, Inc. reported quarterly earnings of $0.01 per share, exceeding the Zacks Consensus Estimate of a loss of $0.04 per share, marking a significant improvement from a loss of $0.19 per share a year ago, resulting in an earnings surprise of 125% [1] Financial Performance - LifeMD posted revenues of $65.7 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.20%, compared to revenues of $44.14 million in the same quarter last year [2] - Over the last four quarters, the company has exceeded consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - LifeMD shares have increased approximately 52.3% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $64.9 million, and for the current fiscal year, it is $0.06 on revenues of $267.95 million [7] Industry Outlook - The Medical Services industry, to which LifeMD belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook [8]